On January 9, 2020 TScan Therapeutics reported the completion of its Series B raise with the inclusion of Novartis Institutes for BioMedical Research (NIBR), Pitango Venture Capital, and Astellas Venture Management (the wholly-owned venture capital organization of Astellas Pharma Inc) (Press release, TScan Therapeutics, JAN 9, 2020, View Source [SID1234552939]). In addition, Series B investors include 6 Dimensions Capital, Longwood Fund, Bessemer Venture Partners, GV, and Novartis Venture Fund.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We welcome Astellas Venture Management, Pitango and NIBR as new TScan investors into our Series B," said David P. Southwell, President and Chief Executive Officer, TScan. "They join the Series A investors 6 Dimensions, Longwood Fund (our founding investor), Google Ventures, Bessemer, and Novartis Venture Fund. With this round, TScan has raised approximately $60 million in funding and is well positioned to discover novel targets of tumor reactive T-cell receptors (TCRs), and to develop these pairs in both liquid and solid tumor indications in oncology."